- Disease: Acute COVID-19
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Prospective, Single centre
- Objective: To evaluate the risk of breakthrough infection, symptomatic disease, hospitalisation, intensive care admission, and COVID-19 related death in kidney transplant recipients receiving pre-exposure prophylaxis with Tixagevimab/Cilgavimab for COVID-19 in the era of the Kraken variant
- Number of participants enrolled: 34
- Study enrolling from to
- Study includes follow-up for 6 months
Study Data
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Infectious diseases unit
- SARS-CoV-2
- Acute COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Tixagevimab/Cilgavimab
External Links
Other information
The information was provided with the aid of the study investigators
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to